JP2010524952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524952A5 JP2010524952A5 JP2010504191A JP2010504191A JP2010524952A5 JP 2010524952 A5 JP2010524952 A5 JP 2010524952A5 JP 2010504191 A JP2010504191 A JP 2010504191A JP 2010504191 A JP2010504191 A JP 2010504191A JP 2010524952 A5 JP2010524952 A5 JP 2010524952A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91192107P | 2007-04-16 | 2007-04-16 | |
| US60/911,921 | 2007-04-16 | ||
| PCT/US2008/060366 WO2008128231A1 (en) | 2007-04-16 | 2008-04-15 | Pyrimidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010524952A JP2010524952A (ja) | 2010-07-22 |
| JP2010524952A5 true JP2010524952A5 (cg-RX-API-DMAC7.html) | 2011-06-02 |
| JP5635398B2 JP5635398B2 (ja) | 2014-12-03 |
Family
ID=39854302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504191A Expired - Fee Related JP5635398B2 (ja) | 2007-04-16 | 2008-04-15 | ピリミジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8349859B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2154967B9 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5635398B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101424847B1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0809715A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2684470C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2154967T5 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2465673T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20140377T2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009011199A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ580671A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2154967T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2154967E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2455994C2 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2154967T1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI484960B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008128231A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| AR074210A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| AR074209A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
| JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| US8466155B2 (en) | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| CN102070618B (zh) * | 2009-11-23 | 2013-08-21 | 和记黄埔医药（上海）有限公司 | 一种化合物及其晶体 |
| RU2528386C2 (ru) | 2010-05-21 | 2014-09-20 | Кемилиа Аб | Новые производные пиримидина |
| EP2395001A1 (en) | 2010-05-21 | 2011-12-14 | Chemilia AB | Novel pyrimidine derivatives |
| EP2433636A1 (en) * | 2010-09-27 | 2012-03-28 | Medizinische Universität Wien | Treatment of Malignant Diseases |
| US8785467B2 (en) | 2010-09-30 | 2014-07-22 | Merck Sharp & Dohme Corp. | Alkoxy pyrimidine PDE10 inhibitors |
| DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| EP2502924A1 (en) | 2011-03-24 | 2012-09-26 | Chemilia AB | Novel pyrimidine derivatives |
| WO2013054351A1 (en) * | 2011-08-08 | 2013-04-18 | Cadila Healthcare Limited | Heterocyclic compounds |
| EP2711365A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| BR112015010109A2 (pt) | 2012-11-05 | 2017-07-11 | Nant Holdings Ip Llc | derivados de indol-5-ol substituídos e suas aplicações terapêuticas |
| BR112015022307A2 (pt) * | 2013-03-15 | 2017-07-18 | Nantbioscience Inc | derivados substituídos indol-5-ol e as suas aplicações terapêuticas |
| CN105601573B (zh) | 2014-11-24 | 2021-07-02 | 中国科学院上海药物研究所 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
| KR20170122782A (ko) * | 2015-02-27 | 2017-11-06 | 난트바이오사이언스 인코포레이티드 | 키나아제 억제제로서의 피리미딘 유도체 및 그 치료적 용도 |
| WO2017190050A1 (en) | 2016-04-28 | 2017-11-02 | Cornell University | Inhibitors of soluble adenylyl cyclase |
| TW202115042A (zh) * | 2019-06-21 | 2021-04-16 | 大陸商江蘇豪森藥業集團有限公司 | 芳基磷氧化物類衍生物抑制劑、其製備方法和應用 |
| CN111004221B (zh) * | 2019-12-13 | 2021-02-02 | 长治学院 | 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途 |
| CA3202990A1 (en) * | 2020-11-27 | 2022-06-02 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Aminoheteroaryl kinase inhibitors |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| US6235741B1 (en) * | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| IL144745A0 (en) | 1999-02-10 | 2002-06-30 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| US6943161B2 (en) * | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
| MXPA02007957A (es) * | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2002016348A1 (en) * | 2000-08-09 | 2002-02-28 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| JP4253188B2 (ja) * | 2000-12-21 | 2009-04-08 | グラクソ グループ リミテッド | 血管新生制御剤としてのピリミジンアミン |
| JPWO2002070477A1 (ja) * | 2001-03-01 | 2004-07-02 | 小野薬品工業株式会社 | ２−メチルインドール−４−酢酸、その製造方法およびその合成中間体の製造方法 |
| WO2002102783A1 (en) * | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| EP1487824B1 (en) | 2002-03-01 | 2007-06-20 | SmithKline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| JP2005529954A (ja) | 2002-06-17 | 2005-10-06 | スミスクライン ビーチャム コーポレーション | 化学プロセス |
| BR0313059B8 (pt) * | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| BR0313871A (pt) * | 2002-08-30 | 2005-07-19 | Eisai Co Ltd | Derivados aromáticos contendo nitrogênio |
| WO2004032882A2 (en) | 2002-10-10 | 2004-04-22 | Smithkline Beecham Corporation | Chemical compounds |
| RS20050363A (sr) | 2002-11-28 | 2007-11-15 | Schering Aktiengesellschaft, | Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US8084457B2 (en) * | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| CN100584832C (zh) * | 2003-09-18 | 2010-01-27 | 诺瓦提斯公司 | 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类 |
| AU2004291147A1 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Urea derivatives as kinase modulators |
| US7718697B2 (en) | 2003-12-17 | 2010-05-18 | Alcon, Inc. | Method for treating glaucoma comprising administering α-lipoic acid |
| WO2005063739A1 (en) | 2003-12-23 | 2005-07-14 | Pfizer Inc. | Novel quinoline derivatives |
| DE102004044556A1 (de) * | 2004-09-15 | 2006-03-30 | Bayer Healthcare Ag | Behandlung viraler Infektionen durch selektive Zerstörung virusinfizierter Zellen mit Stresskinase-Inhibitoren |
| TW200628463A (en) * | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| AU2005310143A1 (en) * | 2004-11-19 | 2006-06-08 | Synta Pharmaceuticals Corp. | Pyrimidine compounds and uses thereof |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| WO2006071079A1 (en) | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| US20060247263A1 (en) * | 2005-04-19 | 2006-11-02 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2007027238A2 (en) * | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
| JP5118029B2 (ja) | 2005-06-14 | 2013-01-16 | タイゲン バイオテクノロジー カンパニー，リミテッド | ピリミジン化合物 |
| US20090149467A1 (en) * | 2005-09-15 | 2009-06-11 | Merck & Co., Inc. | Tyrosine Kinase Inhibitors |
-
2008
- 2008-04-15 PL PL08745881T patent/PL2154967T3/pl unknown
- 2008-04-15 TW TW097113595A patent/TWI484960B/zh not_active IP Right Cessation
- 2008-04-15 EP EP08745881.6A patent/EP2154967B9/en active Active
- 2008-04-15 MX MX2009011199A patent/MX2009011199A/es active IP Right Grant
- 2008-04-15 ES ES08745881.6T patent/ES2465673T3/es active Active
- 2008-04-15 DK DK08745881.6T patent/DK2154967T5/en active
- 2008-04-15 PT PT87458816T patent/PT2154967E/pt unknown
- 2008-04-15 HR HRP20140377AT patent/HRP20140377T2/hr unknown
- 2008-04-15 JP JP2010504191A patent/JP5635398B2/ja not_active Expired - Fee Related
- 2008-04-15 SI SI200831203T patent/SI2154967T1/sl unknown
- 2008-04-15 KR KR1020097023882A patent/KR101424847B1/ko not_active Expired - Fee Related
- 2008-04-15 WO PCT/US2008/060366 patent/WO2008128231A1/en not_active Ceased
- 2008-04-15 BR BRPI0809715-1A patent/BRPI0809715A2/pt not_active Application Discontinuation
- 2008-04-15 NZ NZ580671A patent/NZ580671A/xx not_active IP Right Cessation
- 2008-04-15 RU RU2009141982/04A patent/RU2455994C2/ru active
- 2008-04-15 CA CA2684470A patent/CA2684470C/en active Active
- 2008-04-16 US US12/103,876 patent/US8349859B2/en not_active Expired - Fee Related
-
2012
- 2012-11-08 US US13/672,078 patent/US8901143B2/en active Active